CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 103 enrolled
Drug / intervention
Double blind dietary intervention with EPA and lipoic aciddietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01138774
NCT01138774N/ACompleted
CompareCT.gov

Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity

Clinica Universidad de Navarra, Universidad de Navarra·interventional·Posted Jun 7, 2010·Updated May 28, 2015

In Brief

A clinical study evaluating Double blind dietary intervention with EPA and lipoic acid for Obesity and 2 related conditions. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The aim of the study is to analyze the effects of Lipoic acid and/or EPA supplementation on weight loss, lipid profile, insulin resistance, oxidative and inflammation parameters, metabolomic profile as well as on adipose tissue gene profile in healthy overweight/obese subjects following an energy-restricted diet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Body Fat, Insulin Resistance
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.1 years ago

Interventions

Double blind dietary intervention with EPA and lipoic aciddietary

Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).